Drug name - Latuda
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(2 years from now) | |
| CN1832946A | SUNOVION PHARMS INC | Method For Producing Imide Compound |
Jul, 2024
(1 year, 9 months from now) | |
| CN100422178C | SUNOVION PHARMS INC | Method For Producing Imide Compound |
Jul, 2024
(1 year, 9 months from now) | |
| IN235208B | SUNOVION PHARMS INC | Process For Producing Imide Compound |
Jul, 2024
(1 year, 9 months from now) | |
| IN200600349P4 | SUNOVION PHARMS INC | Process For Producing Imide Compound |
Jul, 2024
(1 year, 9 months from now) | |
| EP1652848A4 | SUNOVION PHARMS INC | Process For Producing Imide Compound |
Jul, 2024
(1 year, 9 months from now) | |
| EP1652848A1 | SUNOVION PHARMS INC | Process For Producing Imide Compound |
Jul, 2024
(1 year, 9 months from now) | |
| EP1652848B1 | SUNOVION PHARMS INC | Process For Producing Imide Compound |
Jul, 2024
(1 year, 9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(1 year, 4 months from now) | |
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(1 year, 4 months from now) | |
|
US9174975
(Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(1 year, 10 months from now) | |
|
USRE45573
(Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(3 years from now) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(3 years from now) | |
|
US8883794
(Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(4 years from now) | |
|
US8729085
(Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(4 years from now) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(8 years from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(8 years from now) | |
|
US9259423
(Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(9 years from now) | |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia; Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of schizophrenia; Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and/or bipolar disorder; Treatment of schizophrenia with improvement in attention function in schizophrenia; treatment of bipolar depression with improvement in attention function in bipolar disorder
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
| 60MG | TABLET;ORAL | Prescription |
| 80MG | TABLET;ORAL | Prescription |
| 120MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.